MA
TERN

MYDA Advisors’s Terns Pharmaceuticals TERN Stock Holding History

MYDA Advisors’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.11M Buy
+40,000
New +$1.64M 0.35% 67
2024
Q4 		– Sell
-87,500
Closed -$730K – 194
2024
Q3 		$730K Sell
87,500
-52,500
-38% -$432K 0.16% 98
2024
Q2 		$953K Hold
140,000
– – 0.21% 72
2024
Q1 		$918K Sell
140,000
-2,383
-2% -$15.6K 0.26% 70
2023
Q4 		$924K Buy
+142,383
New +$753K 0.31% 54

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

MYDA Advisors's TERN Position: Q1 2026 in Review

MYDA Advisors opened a new position in Terns Pharmaceuticals (TERN) in Q1 2026: 40,000 shares worth $2.11M. The stake represents 0.35% of the portfolio and ranks #67 among its holdings. This is a return to the name: MYDA Advisors previously reported a position in TERN as recently as Q3 2024.

MYDA Advisors first reported a position in TERN in Q4 2023 and has held it in 5 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • MYDA Advisors held 40,000 shares of Terns Pharmaceuticals worth $2.11M as of Q1 2026.
  • Terns Pharmaceuticals was a new MYDA Advisors position in Q1 2026.
  • Terns Pharmaceuticals made up 0.35% of MYDA Advisors's portfolio in Q1 2026, its #67 holding.
  • MYDA Advisors first reported a position in Terns Pharmaceuticals in Q4 2023 and has held it in 5 quarters since.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on MYDA Advisors's 13F filing for Q1 2026, filed 14 May 2026.